Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies

J Exp Med. 2024 Sep 2;221(9):e20240365. doi: 10.1084/jem.20240365. Epub 2024 Jul 17.

Abstract

Autoantibodies neutralizing type I interferons (IFN-Is) can underlie infection severity. Here, we trace the development of these autoantibodies at high-resolution using longitudinal samples from 1,876 well-treated individuals living with HIV over a 35-year period. Similar to general populations, ∼1.9% of individuals acquired anti-IFN-I autoantibodies as they aged (median onset ∼63 years). Once detected, anti-IFN-I autoantibodies persisted lifelong, and titers increased over decades. Individuals developed distinct neutralizing and non-neutralizing autoantibody repertoires at discrete times that selectively targeted combinations of IFNα, IFNβ, and IFNω. Emergence of neutralizing anti-IFNα autoantibodies correlated with reduced baseline IFN-stimulated gene levels and was associated with subsequent susceptibility to severe COVID-19 several years later. Retrospective measurements revealed enrichment of pre-existing autoreactivity against other autoantigens in individuals who later developed anti-IFN-I autoantibodies, and there was evidence for prior viral infections or increased IFN at the time of anti-IFN-I autoantibody triggering. These analyses suggest that age-related loss of self-tolerance prior to IFN-I immune-triggering poses a risk of developing lifelong functional IFN-I deficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Neutralizing* / immunology
  • Autoantibodies* / immunology
  • COVID-19* / immunology
  • Female
  • HIV Infections / immunology
  • Humans
  • Interferon Type I* / immunology
  • Interferon-alpha / immunology
  • Male
  • Middle Aged
  • Retrospective Studies
  • SARS-CoV-2 / immunology

Substances

  • Autoantibodies
  • Interferon Type I
  • Antibodies, Neutralizing
  • Interferon-alpha